Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA

Tomi Suomi; Ubaid Ullah Kalim; Omid Rasool; Asta Laiho; Henna Kallionpää; Mari Vähä-Mäkilä; Mirja Nurmio; Juha Mykkänen; Taina Härkönen; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Jorma Toppari; Mikael Knip; Laura L. Elo; Riitta Lahesmaa

doi:10.2337/dc21-2120

Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA

Tomi Suomi, Ubaid Ullah Kalim, Omid Rasool, Asta Laiho, Henna Kallionpää, Mari Vähä-Mäkilä, Mirja Nurmio, Juha Mykkänen, Taina Härkönen, Heikki Hyöty, Jorma Ilonen, Riitta Veijola, Jorma Toppari, Mikael Knip, Laura L. Elo^*, Riitta Lahesmaa^*

^*Tämän työn vastaava kirjoittaja

Turku Bioscience

Tutkimustuotos: Lehtiartikkeli › Katsaus › Tieteellinen › vertaisarvioitu

3 Lataukset (Pure)

Alkuperäiskieli	Englanti
Sivut	e77-e79
Julkaisu	Diabetes Care
Vuosikerta	45
Numero	4
DOI - pysyväislinkit	https://doi.org/10.2337/dc21-2120
Tila	Julkaistu - huhtik. 2022
OKM-julkaisutyyppi	B1 Artikkeli tiedelehdessä

Pääsy asiakirjaan

10.2337/dc21-2120

Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNALopullinen julkaistu versio, 12,6 MBLisenssi: CC BY

https://urn.fi/URN:NBN:fi-fe2023022228210

Muut tiedostot ja linkit

Linkki julkaisuun Scopuksessa

Viittausmuodot

Suomi, T., Kalim, U. U., Rasool, O., Laiho, A., Kallionpää, H., Vähä-Mäkilä, M., Nurmio, M., Mykkänen, J., Härkönen, T., Hyöty, H., Ilonen, J., Veijola, R., Toppari, J., Knip, M., Elo, L. L., & Lahesmaa, R. (2022). Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA. Diabetes Care, 45(4), e77-e79. https://doi.org/10.2337/dc21-2120

@article{5f7a9ec0845940ec88119e047f8cec92,

title = "Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA",

author = "Tomi Suomi and Kalim, {Ubaid Ullah} and Omid Rasool and Asta Laiho and Henna Kallionp{\"a}{\"a} and Mari V{\"a}h{\"a}-M{\"a}kil{\"a} and Mirja Nurmio and Juha Mykk{\"a}nen and Taina H{\"a}rk{\"o}nen and Heikki Hy{\"o}ty and Jorma Ilonen and Riitta Veijola and Jorma Toppari and Mikael Knip and Elo, {Laura L.} and Riitta Lahesmaa",

note = "Funding Information: This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimuss{\"a}{\"a}ti{\"o}), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jus{\'e}lius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Funding Information: Acknowledgments. The authors are grateful to the families of the DIPP study participants and the study group. The authors also thank the personnel of the HLA laboratory at the University of Turku and the islet autoantibody laboratory at the University of Oulu. Marjo Hakkarainen and Sarita Heinonen from Turku Bioscience Centre are acknowledged for their skillful assistance in the laboratory. Next-generation sequencing was performed at the Finnish Functional Genomics Centre, Turku, part of the Biocenter Finland network. The authors acknowledge the Finnish Centre for Scientific Computing for data analysis servers. Funding. This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimuss€a€atio€), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jus{\'e}lius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. T.S. and U.U.K. designed experiments, analyzed the data, prepared the figures, and wrote the manuscript. O.R. designed experiments, analyzed data, and wrote the manuscript. A.L., H.K., M.V.-M., M.N., J.M., and T.H. contributed to the design of the study and analysis. H.H., J.I., R.V., J.T., and M.K. were responsible for the DIPP cohort. R.V. and M.K. were responsible for the islet autoantibody analyses. All authors contributed to the final version of the manuscript. R.L. initiated, designed, and supervised the study. L.L.E. participated in the design of the study and analysis and supervised the study. R.L. and L.L.E. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Data and Resource Availability. Analyzed count data from miRNA-seq of the discovery cohort (87 samples from four case-control pairs) and the validation cohort (56 samples from 14 pairs) can be accessed from the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) using the accession codes E-MTAB-10959 and E-MTAB-10968, respectively. Other data generated during the current study are available from the corresponding author on reasonable request.",

year = "2022",

month = apr,

doi = "10.2337/dc21-2120",

language = "English",

volume = "45",

pages = "e77--e79",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "4",

}

Suomi, T, Kalim, UU, Rasool, O, Laiho, A, Kallionpää, H, Vähä-Mäkilä, M, Nurmio, M, Mykkänen, J, Härkönen, T, Hyöty, H, Ilonen, J, Veijola, R, Toppari, J, Knip, M, Elo, LL & Lahesmaa, R 2022, 'Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA', Diabetes Care, Vuosikerta 45, Nro 4, Sivut e77-e79. https://doi.org/10.2337/dc21-2120

TY - JOUR

T1 - Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA

AU - Suomi, Tomi

AU - Kalim, Ubaid Ullah

AU - Rasool, Omid

AU - Laiho, Asta

AU - Kallionpää, Henna

AU - Vähä-Mäkilä, Mari

AU - Nurmio, Mirja

AU - Mykkänen, Juha

AU - Härkönen, Taina

AU - Hyöty, Heikki

AU - Ilonen, Jorma

AU - Veijola, Riitta

AU - Toppari, Jorma

AU - Knip, Mikael

AU - Elo, Laura L.

AU - Lahesmaa, Riitta

N1 - Funding Information: This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimussäätiö), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jusélius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Funding Information: Acknowledgments. The authors are grateful to the families of the DIPP study participants and the study group. The authors also thank the personnel of the HLA laboratory at the University of Turku and the islet autoantibody laboratory at the University of Oulu. Marjo Hakkarainen and Sarita Heinonen from Turku Bioscience Centre are acknowledged for their skillful assistance in the laboratory. Next-generation sequencing was performed at the Finnish Functional Genomics Centre, Turku, part of the Biocenter Finland network. The authors acknowledge the Finnish Centre for Scientific Computing for data analysis servers. Funding. This research was supported by the Academy of Finland, including InFLAMES, SYMMyS, and personalized medicine programs (grant numbers 337530, 292482, 250114, 292482, 294337, 292335, 319280, 314444, 329277, 331790, 296801, 304995, 310561, 314443, and 329278), JDRF, including grants 1-SRA-2016-342-M-R and 1-SRA-2019-732-M-B, the Diabetes Research Foundation (Diabetestutkimuss€a€atio€), the Novo Nordisk Foundation, the Finnish Cancer Foundation, the Sigrid Jusélius Foundation, the Pediatric Research Foundation, Turku University Hospital Special Governmental Grants, and the Special Research Funds for University Hospitals in Finland. This research was also supported by grants from the European Research Council (677943), European Union's Horizon 2020 Research and Innovation Programme (955321), and the European Foundation for the Study of Diabetes. Biocenter Finland and ELIXIR Finland also support our research. Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. T.S. and U.U.K. designed experiments, analyzed the data, prepared the figures, and wrote the manuscript. O.R. designed experiments, analyzed data, and wrote the manuscript. A.L., H.K., M.V.-M., M.N., J.M., and T.H. contributed to the design of the study and analysis. H.H., J.I., R.V., J.T., and M.K. were responsible for the DIPP cohort. R.V. and M.K. were responsible for the islet autoantibody analyses. All authors contributed to the final version of the manuscript. R.L. initiated, designed, and supervised the study. L.L.E. participated in the design of the study and analysis and supervised the study. R.L. and L.L.E. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Data and Resource Availability. Analyzed count data from miRNA-seq of the discovery cohort (87 samples from four case-control pairs) and the validation cohort (56 samples from 14 pairs) can be accessed from the ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) using the accession codes E-MTAB-10959 and E-MTAB-10968, respectively. Other data generated during the current study are available from the corresponding author on reasonable request.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85128160256&partnerID=8YFLogxK

U2 - 10.2337/dc21-2120

DO - 10.2337/dc21-2120

M3 - Letter

C2 - 35134118

AN - SCOPUS:85128160256

SN - 0149-5992

VL - 45

SP - e77-e79

JO - Diabetes Care

JF - Diabetes Care

IS - 4

ER -